Paris, January 2026 – Delbert Pharma, a French pharmaceutical company dedicated to safeguarding essential medicines, announces a partnership with the Kent Athlone Pharma Group for the Distribution and Marketing of the injectable aztreonam (Azactam®) in the UK and Ireland
Delbert Pharma acquired Azactam® from Bristol Myers Squibb in December 2024.
Appointing Kent Athlone Pharma Group to market & distribute Azactam® in the UK and Ireland, reflects the company’s strong track record and capabilities commercialising specialty hospital medicines.
For Kent Athlone Pharma Group, the addition of Azactam® injection enhances and compliments the company’s existing anti-infective injectable portfolio.
“Partnering with Kent Athlone Pharma Group marks a significant step in Delbert Pharma’s international growth strategy. We are proud to bring Azactam® back to patients in the UK and Ireland with a trusted partner who shares our commitment to ensuring continuous access to essential hospital medicines.”
stated Eric Fidelin, Executive General Director of Delbert Pharma.
“The addition of Azactam® injection enhances and compliments the company’s existing anti-infective injectable portfolio. We look forward to working with Delbert Pharma to ensure continued access for patients in the UK and Ireland to this important medicine”.
said David Wright Chief Business Officer of the Kent Athlone Pharma Group
About Delbert Pharma
Delbert Pharma is an independent French pharmaceutical company founded in 2013 and a mission-driven company since 2023, dedicated to preserving essential medicines for the stability of healthcare systems. Delbert Pharma offers a broad range of treatments in infectious diseases, neurology, and onco-haematology, addressing critical medical needs in Europe and beyond. The company is strongly committed to combating medicine shortages and fostering pharmaceutical reindustrialization.
About Kent Athlone Pharma Group
Kent Athlone Pharma Group is a privately owned asset-light, European specialty pharmaceutical company with offices in the UK (Corporate HQ) and Ireland (EU office). The company is focused on developing, licensing, launching, and commercialising Value Added Medicines to meet the needs of customers and patients in the UK, Ireland and Europe.